Trial Profile
Affirm: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Patients With Progressive Castration-resistant Prostate Cancer Previously Treated With Docetaxel Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jun 2022
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms AFFIRM
- Sponsors Medivation; Pfizer
- 25 May 2022 Results of post hoc, pooled, retrospective analysis from AFFIRM, PREVAIL and PROSPER examining the association of statin and metformin on radiographic progression-free survival , metastasis-free survival, toxicity and overall survival, published in the European Journal of Cancer
- 29 Dec 2021 Results of post hoc analysis assessing effect of concurrent corticosteroid use on enzalutamide-treated patients published in the Clinical Cancer Research
- 21 Sep 2020 Results assessing Impact of enzalutamide on patient-reported fatigue from ARCHES, PROSPER, PREVAIL, and AFFIRM presented at the 45th European Society for Medical Oncology Congress